Page last updated: 2024-11-05

4-chlorobenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7726
CHEMBL ID1474
SCHEMBL ID1919
MeSH IDM0147908

Synonyms (69)

Synonym
benzaldehyde, p-chloro-
nsc-2078
nsc2078
benzaldehyde, 4-chloro-
p-chlorobenzaldehyde
pcad
4-chlorobenzoic aldehyde
p-chlorobenzenecarboxaldehyde
inchi=1/c7h5clo/c8-7-3-1-6(5-9)2-4-7/h1-5
NCGC00091804-01
ai3-52280
nsc 2078
einecs 203-247-4
4-chlorobenzenaldehyde
ccris 857
4-chlorobenzaldehyde
C06648
104-88-1
4-chlorobenzaldehyde, 97%
STK200392
AC-11571
CHEMBL1474
AKOS000118927
FT-0664560
NCGC00091804-03
NCGC00091804-02
4-chloro-benzaldehyde
cas-104-88-1
NCGC00257690-01
dtxsid2021860 ,
tox21_200136
dtxcid501860
BMSE001029
para-chlorobenzaldehyde
e67727up9z ,
unii-e67727up9z
ec 203-247-4
FT-0618168
SCHEMBL1919
4-chlorobenzaldehye
4-chlorobezaldehyde
parachlorobenzaldehyde
rho-chlorobenzaldehyde
p-chloro-benzaldehyde
4-chloro benzaldehyde
p-chloro benzaldehyde
(4-chlorophenyl)methanone
(4-chloro-phenyl)-methanone
4-chlorobenzaldehyd
4-chlorbenzaldehyd
chlorobenzaldehyde, 4-
1-chloro-4-formylbenzene
chlorobenzaldehyde, p-
4-formylphenyl chloride
p-chlorophenylaldehyde
alfentanilhydrochloride
STR00145
W-108802
PS-9029
mfcd00003379
CS-W008778
F2190-0600
D77694
BCP25775
benzaldehyde,p-chloro-
Q2154695
EN300-18419
4-formylchlorobenzene
Z57772447
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.54810.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
Chain B, HADH2 proteinHomo sapiens (human)Potency39.81070.025120.237639.8107AID886
AR proteinHomo sapiens (human)Potency10.90030.000221.22318,912.5098AID743036; AID743040
estrogen nuclear receptor alphaHomo sapiens (human)Potency5.46190.000229.305416,493.5996AID743075
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency30.45100.001723.839378.1014AID743083
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency43.01320.000323.4451159.6830AID743065
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.05310.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (13)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (10)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (4)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID299876Antiinflammatory activity against xylene-induced ear edema in Kunming mouse assessed as edema weight at 20 mg/kg, po after 2 hrs relative to control2007Bioorganic & medicinal chemistry, Jul-15, Volume: 15, Issue:14
Toward the development of chemoprevention agents. Part 1: Design, synthesis, and anti-inflammatory activities of a new class of 2,5-disubstituted-dioxacycloalkanes.
AID1656235Cytotoxicity against mouse B16F10 cells assessed as reduction in cell viability2019European journal of medicinal chemistry, Feb-15, Volume: 164Green recipes to quinoline: A review.
AID1544945Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding at 1 uM incubated for 4 hrs in presence of NO711 by LC-ESI-MS/MS analysis relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
AID1337095Inhibition of human MPO2017ACS medicinal chemistry letters, Feb-09, Volume: 8, Issue:2
From Dynamic Combinatorial Chemistry to
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (9.09)18.7374
1990's0 (0.00)18.2507
2000's1 (9.09)29.6817
2010's7 (63.64)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.92

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.92 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index84.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.92)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (8.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]